SpyGlass Pharma, Inc. Common Stock
NASDAQ Global MarketTotal Valuation
SpyGlass Pharma, Inc. Common Stock carries a market capitalization of 967.56M, placing it among publicly traded companies globally. Its enterprise value stands at 511.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 967.56M |
| Enterprise Value | 511.96M |
Share Statistics
SpyGlass Pharma, Inc. Common Stock currently has 33.45M shares outstanding.
| Shares Outstanding | 33.45M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 3.20 |
| P/TBV Ratio | 3.20 |
| P/FCF Ratio | -12.76 |
| P/OCF Ratio | -12.76 |
Financial Position
SpyGlass Pharma, Inc. Common Stock maintains a current ratio of 25.06, meaning it holds 25.1x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 25.06 |
| Quick Ratio | 24.89 |
| Debt / Equity | 0.70 |
| Debt / EBITDA | -0.03 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -84.12 |
| Return on Assets (ROA) | -138.07 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
SpyGlass Pharma, Inc. Common Stock's stock has gained approximately 9.62121% over the past 52 weeks. The 50-day moving average sits at 23.18, while the 200-day moving average is 23.55.
| Beta (5Y) | N/A |
| 52-Week Price Change | 9.62121% |
| 50-Day Moving Average | 23.18 |
| 200-Day Moving Average | 23.55 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -61.09M, while operating income came in at -62.10M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -62.10M |
| Pretax Income | -56.05M |
| Net Income | -56.05M |
| EBITDA | -61.09M |
| EBIT | -62.10M |
| Earnings Per Share (EPS) | -2.10 |
Balance Sheet
SpyGlass Pharma, Inc. Common Stock holds 234.19M in cash and equivalents against 1.63M in total debt, resulting in a net debt position of -223.14M. Total book value stands at 232.36M, with working capital of 227.02M providing operational flexibility.
| Cash & Cash Equivalents | 234.19M |
| Total Debt | 1.63M |
| Net Debt | -223.14M |
| Equity (Book Value) | 232.36M |
| Book Value Per Share | 6.95 |
| Working Capital | 227.02M |
Cash Flow
SpyGlass Pharma, Inc. Common Stock produced -46.56M in operating cash flow over the past twelve months.
| Operating Cash Flow | -46.56M |
| Capital Expenditures | N/A |
| Free Cash Flow | -46.56M |
| FCF Per Share | -1.74 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -21.04 |
| FCF Yield | -7.84 |
Scores
SpyGlass Pharma, Inc. Common Stock posts an Altman Z-Score of 39.84, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 39.84 |